Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals

Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals

Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical manifestations. An elevation of liver damage markers has been observed in numerous cases, which could be related to the empirical use of potentially hepatotoxic drugs. The aim of this study was to describe the clinical and analytica...

Full description

Bibliographic Details
Main Authors:	Ana Delgado, Stefan Stewart, Mikel Urroz, Amelia Rodríguez, Alberto M. Borobia, Ibtissam Akatbach-Bousaid, Miguel González-Muñoz, Elena Ramírez
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Journal of Clinical Medicine
Subjects:	coronavirus disease 2019 (COVID-19) drug induced liver injury (DILI) pharmacovigilance updated Roussel Uclaf Causality Assessment Method (RUCAM) lymphocyte transformation test (LTT)
Online Access:	https://www.mdpi.com/2077-0383/10/19/4432

Similar Items

Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study
by: Amelia Rodríguez, et al.
Published: (2022-03-01)

A case report of a drug‐induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing
by: Miguel González‐Muñoz, et al.
Published: (2020-12-01)

Idiosyncratic DILI and RUCAM under One Hat: The Global View
by: Rolf Teschke, et al.
Published: (2023-08-01)

Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future
by: Gaby Danan, et al.
Published: (2019-07-01)

Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019
by: Rolf Teschke
Published: (2019-07-01)

Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method
by: Rolf Teschke, et al.
Published: (2022-04-01)

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis
by: Rolf Teschke, et al.
Published: (2020-09-01)

Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM
by: Xiaoping Shi, et al.
Published: (2021-11-01)

The LiverTox Paradox-Gaps between Promised Data and Reality Check
by: Rolf Teschke, et al.
Published: (2021-09-01)

Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM
by: Marlene Plüß, et al.
Published: (2022-08-01)

Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature
by: Hana Studentova, et al.
Published: (2022-02-01)

Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment
by: Cheng-Maw Ho, et al.
Published: (2021-07-01)

Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method
by: Laura Pedraza, et al.
Published: (2021-02-01)

Treatment of Drug-Induced Liver Injury
by: Rolf Teschke
Published: (2022-12-01)

Impact of pharmacist active consultation on clinical outcomes and quality of medical care in drug-induced liver injury inpatients in general hospital wards: A retrospective cohort study
by: Dongxuan Li, et al.
Published: (2022-08-01)

Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM
by: Francisco Andújar-Vera, et al.
Published: (2023-09-01)

Distinction of Drug-Induced Liver Injury From Autoimmune Hepatitis in Patients With Acute Liver Injury: Proposal of a Combination of Diagnostic Scores
by: Keisuke Kakisaka, et al.
Published: (2023-01-01)

Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature
by: Taylor A. Ault, et al.
Published: (2023-02-01)

A case of carbamazepine-induced severe cholestatic hepatitis: Case report and review of literature
by: Suhas Ganesh, et al.
Published: (2017-01-01)

Complex liver injury induced by combined Aloe Vera and vitamin A oral supplements, as assessed by histology and the updated RUCAM
by: Katerina Delladetsima, et al.
Published: (2022-04-01)

Case series and review of Ayurvedic medication induced liver injury
by: Christopher M. Karousatos, et al.
Published: (2021-03-01)

Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review
by: Miriam Hussein, et al.
Published: (2023-05-01)

Multi-Omics Integration to Reveal the Mechanism of Hepatotoxicity Induced by Dictamnine
by: Can Tu, et al.
Published: (2021-09-01)

Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use
by: Rolf Teschke, et al.
Published: (2023-06-01)

Drug-induced liver injury associated with dacomitinib: A case report
by: Xuanxuan Wang, et al.
Published: (2022-09-01)

Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment—A Study from Patients of Portuguese Health Centers
by: Maria João Cavaco, et al.
Published: (2022-05-01)

Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis
by: Linnea A. Swanson, et al.
Published: (2022-10-01)

Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study
by: Ming-Gui Wang, et al.
Published: (2022-11-01)

Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update
by: Rolf Teschke, et al.
Published: (2021-09-01)

Pharmacovigilance and assessment of drug safety reports during COVID 19
by: Mira K Desai
Published: (2020-01-01)

A concept for causality assessment and causal inference of adverse events cases
by: Ahmed Al-Imam, et al.
Published: (2022-11-01)

A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale
by: Xiaoping Shi, et al.
Published: (2022-04-01)

Organisation of the Russian Pharmacovigilance System: Survey of Pharmacovigilance Officers
by: A. E. Krasheninnikov, et al.
Published: (2021-10-01)

Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP
by: Chris Weir, et al.
Published: (2022-10-01)

COVID-19 (SARS-CoV-2) lymphocyte responses are associated with inflammatory biomarkers in total joint replacement surgery candidates pre-operatively
by: Marco S. Caicedo, et al.
Published: (2021-06-01)

Xiao-Yao-San protects against anti-tuberculosis drug-induced liver injury by regulating Grsf1 in the mitochondrial oxidative stress pathway
by: Zijun Bai, et al.
Published: (2022-09-01)

Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause
by: Goran Bokan, et al.
Published: (2023-08-01)

Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method
by: Ling Ye, et al.
Published: (2021-12-01)

The pharmacovigilance of psychoactive medications in Brazil
by: Elisaldo Luiz de Araújo Carlini, et al.
Published: (2003-10-01)

Preparation for the Inspection of the Pharmacovigilance System
by: B. K. Romanov
Published: (2021-10-01)